Lixte Biotechnology, Inc. - Utang jangka cendhak perusahaan LIXT

The lack of stable cash flow due to the clinical status of its developments makes Lixte Biotechnology (LIXT) dependent on external funding. Current short-term liabilities displayed on the GURU.Markets platform confirm this hypothesis, with the latest value recorded as 0.00. The business relies on licensing inhibitor formulas to third-party behemoths, while scalability is driven by global sales of patented drugs with minimal production costs.

Geopolitical tensions and sanctions are complicating the logistics of reagents for Lixte Biotechnology (LIXT) oncology research, directly impacting operating expenses. The short-term debt time series captures obligations of up to one year; a decrease in this metric could signal either a post-crisis balance sheet recovery or a loss of access to credit, which is critical if drug development timelines are extended.